← Back to Home

Can Eliminating Individual Metastases Extend Survival? Randomized Breast Cancer Trial Finds No Added Benefit

When breast cancer involves only a few metastatic lesions, targeting every tumor may seem to offer a chance to change the course of the disease. Yet NRG-BR002 did not establish that adding radiation therapy or surgery improves survival; tumor cells in the blood may offer clues for future research.

By SURL BioNews

If imaging shows only a few remaining metastatic tumors, could eliminating them one by one give patients more time? This has long been an important question in the treatment of oligometastatic breast cancer. Now, the randomized NRG-BR002 trial offers a cautious answer: adding radiation therapy or surgery directed at metastatic lesions to first-line systemic therapy showed no additional improvement in progression-free survival or overall survival.

MD Anderson Cancer Center released an announcement on October 7, and Newswise carried the same research announcement, stating that the results had been published in the *Journal of Clinical Oncology*. The trial enrolled 129 patients at 47 institutions in the United States and Canada, of whom 125 were eligible for analysis. All participants had four or fewer metastatic lesions and were randomly assigned to receive systemic therapy alone or systemic therapy plus stereotactic body radiation therapy (SBRT) or surgery to treat all known metastatic lesions.

Median progression-free survival was 23 months in the group receiving systemic therapy alone and 19.5 months in the group receiving additional local ablative therapy. There was also no significant difference in overall survival between the two groups. The study did not achieve the improvement required for its primary endpoint and therefore did not proceed to the originally planned phase III stage. These figures support the conclusion that “no added benefit was established”; the difference in medians alone does not establish that local treatment causes the disease to progress more quickly.

The results also reveal the gap between local control and the systemic course of the disease. Radiation therapy or surgery can control individual lesions, but according to the center’s announcement, longer follow-up still found no significant improvement in progression-free survival and no evidence of fewer new metastases. This suggests that treating tumors visible on imaging may not be enough to prevent the disease from continuing to develop elsewhere.

On this basis, the research team concluded that, outside clinical trials, radiation therapy or surgery directed at metastatic lesions should not routinely be added for these patients with the aim of extending survival. However, local treatment still has a role when individual lesions cause pain or other symptoms. The trial addressed whether additional treatment could improve the overall course of the disease; it did not negate the value of symptom relief, and its conclusions should not be directly extended to all cancer types or treatment settings.

An exploratory analysis offered a new direction for research: patients with no circulating tumor cells, or only very low levels, in their blood before treatment appeared more likely to benefit from treatment directed at metastatic lesions. Circulating tumor cells are cancer cells that have entered the bloodstream. This finding suggests that selecting patients may require more than simply counting lesions. However, the announcement did not provide the full sample size or effect estimates for this analysis, leaving insufficient evidence to establish clinical selection criteria.

NRG-BR002 thus takes the question to a more precise level: which patients have disease characteristics that might allow local treatment to truly alter the course of their disease? Current randomized evidence does not support broadly increasing treatment intensity. Identifying the small subset who might benefit will still require validation in new trials with prespecified biomarkers and analytical methods.

References

  1. MD Anderson Cancer Center / Newswise
  2. The University of Texas MD Anderson Cancer Center